[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
U Hennrich, M Eder - Pharmaceuticals, 2022 - mdpi.com
In March 2022,[177Lu] Lu-PSMA-617 (PluvictoTM) was approved by the FDA for the
treatment of prostate cancer patients. Until now, the approval has been limited to patients …
treatment of prostate cancer patients. Until now, the approval has been limited to patients …
Lutetium Lu 177 vipivotide tetraxetan: first approval
SJ Keam - Molecular diagnosis & therapy, 2022 - Springer
Lutetium Lu 177 vipivotide tetraxetan (PLUVICTO™, formerly known as 177Lu-PSMA-617)
is a radioligand therapeutic agent that is being developed by Advanced Accelerator …
is a radioligand therapeutic agent that is being developed by Advanced Accelerator …
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
C Kratochwil, WP Fendler, M Eiber, MS Hofman… - European journal of …, 2023 - Springer
Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically
significant prostate adenocarcinomas, and patients with target-positive disease can easily …
significant prostate adenocarcinomas, and patients with target-positive disease can easily …
Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation
J Sun, Z Huangfu, J Yang, G Wang, K Hu, M Gao… - Advanced Drug Delivery …, 2022 - Elsevier
Since the first introduction of sodium iodide I-131 for use with thyroid patients almost 80
years ago, more than 50 radiopharmaceuticals have reached the markets for a wide range …
years ago, more than 50 radiopharmaceuticals have reached the markets for a wide range …
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review
Introduction Metastatic castrate resistant prostate cancer (mCPRC) remains an aggressive
form of prostate cancer that no longer responds to traditional hormonal treatment alone …
form of prostate cancer that no longer responds to traditional hormonal treatment alone …
Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression
X Wen, P Xu, X Zeng, J Liu, C Du, X Zeng… - European Journal of …, 2023 - Springer
Purpose Evans blue as an albumin binder has been widely used to improve
pharmacokinetics and enhance tumor uptake of radioligands, including prostate-specific …
pharmacokinetics and enhance tumor uptake of radioligands, including prostate-specific …
Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate …
Abstract Purpose Actinium-225-labeled prostate-specific membrane antigen ([225Ac] Ac-
PSMA-617) is safe and effective in the treatment of metastatic castration-resistant prostate …
PSMA-617) is safe and effective in the treatment of metastatic castration-resistant prostate …
[HTML][HTML] [161Tb] Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu] Lu …
A Schaefer-Schuler, C Burgard, A Blickle, S Maus… - Theranostics, 2024 - ncbi.nlm.nih.gov
Rationale: Evaluation of alternative radionuclides for use in prostate-specific membrane
antigen (PSMA)-targeted radioligand therapy (RLT) is currently focusing on 161 Tb, which …
antigen (PSMA)-targeted radioligand therapy (RLT) is currently focusing on 161 Tb, which …
Predictors and real-world use of prostate-specific radioligand therapy: PSMA and beyond
PSMA is a transmembrane protein that is markedly overexpressed in prostate cancer,
making it an excellent target for imaging and treating patients with prostate cancer. Several …
making it an excellent target for imaging and treating patients with prostate cancer. Several …